Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with b-catenin (ctnnb1) status

Cancer Research

Volumn 73, Issue 5, 2013, Pages 1600-1610

  Morikawa, Teppei ^a   Kuchiba, Aya ^a   Lochhead, Paul ^a   Nishihara, Reiko ^a   Yamauchi, Mai ^a   Imamura, Yu ^a   Liao, Xiaoyun ^a   Qian, Zhi Rong ^a   Ng, Kimmie ^a   Chan, Andrew T ^b,d   Meyerhardt, Jeffrey A ^a   Giovannucci, Edward ^b,e,f   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,c,e,g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Departments of Epidemiology   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER RISK; CANCER TISSUE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMOBILIZATION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

BETA CATENIN; BODY MASS INDEX; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MOTOR ACTIVITY; PROSPECTIVE STUDIES; RISK FACTORS; WNT SIGNALING PATHWAY;

EID: 84874927068     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2276     Document Type: Article

References (50)

1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and metaanalysis of prospective observational studies. Lancet 2008;371: 569-78.
2. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. Am J Clin Nutr 2007;86: 556-65.
3. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: A meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-47.
4. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: Findings from 56 observational studies. Obes Rev 2010;11:19-30.
5. Spence RR, Heesch KC, Brown WJ. A systematic review of the association between physical activity and colorectal cancer risk. Scand J Med Sci Sports 2009;19:764-81.
6. Harriss DJ, Atkinson G, Batterham A, George K, Cable NT, Reilly T, et al. Lifestyle factors and colorectal cancer risk (2): A systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis 2009;11:689-701.
7. Boyle T, Fritschi L, Heyworth J, Bull F. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol 2011;173:1183-91.
8. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: A systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1548-61.
9. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11: 886-95.
10. Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, et al. A large prospective study of meat consumption and colorectal cancer risk: An investigation of potential mechanisms underlying this association. Cancer Res 2010;70:2406-14.
11. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 2011;71: 197-205.
12. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98.
13. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab 2009;20:16-24.
14. Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI, et al. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res 2012;72:3607-17.
15. Liu Z, Brooks RS, Ciappio ED, Kim SJ, Crott JW, Bennett G, et al. Diet-induced obesity elevates colonic TNF-alpha in mice and is accompanied by an activation of Wnt signaling: A mechanism for obesity-associated colorectal cancer. J Nutr Biochem 2012;23: 1207-13.
16. Ju J, Nolan B, Cheh M, Bose M, Lin Y, Wagner GC, et al. Voluntary exercise inhibits intestinal tumorigenesis in Apc(Min/) mice and azoxymethane/dextran sulfate sodium-treated mice. BMC Cancer 2008;8:316.
17. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-94.
18. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
19. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1990;1:466-73.
20. Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst 2012;104:415-20.
21. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81-6.
22. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, et al. Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25: 71-80.
23. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61: 847-54.
24. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: A tale of two sides or a continuum? Gut 2012;61:794-7.
25. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356: 2131-42.
26. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Meyerhardt JA, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007;9:569-77.
27. Lin JH, Morikawa T, Chan AT, Kuchiba A, Shima K, Nosho K, et al. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 2012; 72:3020-8.
28. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72:3-12.
29. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A 2000;97: 12103-8.
30. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001;20: 252-9.
31. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-7.
32. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
33. Ogino S, Giovannucci E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 2012;41: 1072-4.
34. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-8.
35. Hughes LA, Simons CC, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruine AP, et al. Body size, physical activity and risk of colorectal cancer with or without the CpGisland methylator phenotype (CIMP). PLoS ONE 2011;6:e18571.
36. Hughes LA, Williamson EJ, van Engeland M, Jenkins MA, Giles GG, Hopper JL, et al. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: A pooled analysis. Int J Epidemiol 2012;41:1060-72.
37. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut 2012;61:1299-305.
38. Limburg PJ, Limsui D, Vierkant RA, Tillmans L, Wang AH, Lynch CF, et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev 2012;21: 681-4.
39. Gay LJ, Mitrou PN, Keen J, Bowman R, Naguib A, Cooke J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol 2012;228:405-15.
40. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011;8:711-9.
41. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am J Epidemiol 2012;176:659-67.
42. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012;30:42-52.
43. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: Past, present and future. Pathology Research International 2011;2011:902674.
44. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim Biophys Acta 2012;1825:77-85.
45. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw 2011;9:1293-302.
46. Ku CS, Cooper DN,WuM, Roukos DH, Pawitan Y, Soong R, et al. Gene discovery in familial cancer syndromes by exome sequencing: Prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012;25:1055-68.
47. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: Review and recommendations from an expert panel. Am J Gastroenterol 2012;107:1315-29.
48. Greystoke A, Mullamitha SA. How many diseases are colorectal cancer? Gastroenterol Res Pract 2012;2012:564741.
49. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012;9:561-70.
50. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: A worldwide task force. J Transl Med 2012;10:205.